Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
1763 - 1766
MetadataShow full item record
AuthorsFreeman, CL; Dixon, M; Houghton, R; Kreuzer, K-A; Fingerle-Rowson, G; Herling, M; Humphrey, K; Böttcher, S; de Costa, CS; Iglesias, V; Stilgenbauer, S; Gribben, J; Hallek, M; Goede, V
- College Publications